PACAP38 is a potent inducer of migraine attacks with an increased selectivity towards PAC1R. Therefore, inhibition of the receptor is probed for migraine, e.g., by anti-PAC1R antibodies AMG 301 (phase II completed 2019) [84] or by the development of small-molecule antagonists [85]. Here, ADCYAP1R1 is linked to migraine disorder.